HK Stock MarketDetailed Quotes

KEYMED BIO-B (02162)

Watchlist
  • 75.000
  • +2.950+4.09%
Market Closed Apr 10 16:08 CST
22.41BMarket Cap-38.72P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

KEYMED BIO-B (02162) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
Cooperative income401.55M56.06%
Drug sales314.76M43.94%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Cooperative income401.55M56.06%
Drug sales314.76M43.94%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
United States of America393.67M54.96%
The mainland of China322.17M44.98%
Britain474K0.07%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +5.26%
Sample Name
Sample Code
 -2.00%
Sample Name
Sample Code
 -4.69%
4
SINOPEC CORP
00386
-8.50%
5
KUNLUN ENERGY
00135
-10.30%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +21.11%
Sample Name
Sample Code
 +15.55%
Sample Name
Sample Code
 +8.32%
4
Rockchip Electronics
603893
+0.17%
5
Hangzhou Shunwang Technology
300113
-4.38%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -